Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acusphere Left Unstable By FDA Panel Review; CEO Turns Ire On Panelists

Executive Summary

Acusphere is evaluating its viability after an FDA advisory panel voted against its lead product Imagify Dec. 10, and amid failing investor confidence. CEO Sherri Oberg held an emotional next-day conference call to discuss next steps for the Watertown, Mass.-based firm
Advertisement

Related Content

Acusphere Future Up In Air After Imagify Fails Before Advisory Panel
Acusphere Future Up In Air After Imagify Fails Before Advisory Panel
Acusphere Future Up In Air After Imagify Fails Before Advisory Panel
Acusphere Secures Funding From Cephalon To See Imagify Through PDUFA
Advertisement
UsernamePublicRestriction

Register

PS050430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel